Spruce Biosciences is a clinical-stage company focused on developing and commercializing novel therapies for rare endocrine disorders, with its lead product candidate tildacerfont. Tildacerfont is an oral, second-generation CRF1 receptor antagonist and the first non-steroidal molecule to demonstrate the ability to normalize elevated androgens in patients with congenital adrenal hyperplasia (CAH) in clinical studies. The company plans to advance a late-stage clinical program in adults with classic CAH to evaluate whether tildacerfont can reduce chronic glucocorticoid steroid usage and improve clinical outcomes, and to complete proof-of-concept trials in pediatric patients. Spruce also intends to evaluate tildacerfont in other diseases impacted by elevated ACTH or adrenal androgens. Tildacerfont has been granted orphan drug status by both the FDA and EMA. The recent financing will support continued clinical development and pivotal programs for the product candidate.

Total raised

$88M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2020